Development of combination therapy against influenza pneumonia
This invention offers a novelcombination therapy for influenza pneumonia. The drugs used in this combinationtherapy targets both neutrophil-induced ARDS and the virus itself, providing ahost of beneficial synergistic effects. According to the invention, a novel combinationtherapy targeting the host response has been used in combination with anantiviral agent, oseltamivir, for the treatment of severe influenza infectionin mice. Based on the findings, dual-treatment significantly enhances thesurvival of mice after lethal influenza challenge, when compared to treatmentof anti-viral alone.
Reduced neutrophil influxDecreased vascular leakageDecreased endothelial damageDecreased release of NETsSynergistic therapeutic increases survival in mice
Therapeutictreatment for influenza pneumonia
None
美國
